Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a strong sell rating to a hold rating in a research report sent to investors on Saturday.

Other equities research analysts also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a report on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

Citius Pharmaceuticals Trading Up 5.0%

Citius Pharmaceuticals stock opened at $0.84 on Friday. The company has a market capitalization of $17.46 million, a price-to-earnings ratio of -0.25 and a beta of 1.51. Citius Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $5.95. The stock’s 50 day moving average is $1.24 and its 200-day moving average is $1.31.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of large investors have recently bought and sold shares of CTXR. NewEdge Advisors LLC bought a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $40,000. XTX Topco Ltd bought a new position in Citius Pharmaceuticals in the second quarter valued at approximately $32,000. Finally, Arkadios Wealth Advisors increased its stake in Citius Pharmaceuticals by 100.0% in the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after acquiring an additional 10,000 shares during the last quarter. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.